For instance, SB vectors with anti-CD19 have been successful in generating functional CAR T cells (47,48) and have shown safety in adjuvant therapy for patients with B cell-Acute Lymphoblastic Leukemia (B-ALL) and non-Hodgkin's Lymphoma (NHL) (49). Here, CD19 is linked to non-Hodgkin lymphoma.